Compare Bristol-Myers Squibb Co (BMY) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Lufax Holding Ltd — how do they compare? Bristol-Myers Squibb Co trades at $63.61 (market cap $132.45B), while Lufax Holding Ltd trades at $1.56 (market cap $2.41B). The key difference: Bristol-Myers Squibb Co is far larger — about 55× Lufax Holding Ltd's market cap, and Bristol-Myers Squibb Co pays a 3.89% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals.
| BMY | LU | |
|---|---|---|
Market Cap | $132.45B | $2.41B |
Sector | Health | Technology |
52-Week High | $65.89 | $4.40 |
52-Week Low | $42.60 | $1.23 |
Enterprise Value | $166.44B | — |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LU trades at $1.50, up 0.67% on the day, with a neutral technical signal and bearish moving averages. The stock shows deep value on price-to-sales (0.42) and price-to-book (0.12) ratios but faces profitability challenges with a -9.08% net margin and negative ROE. Recent earnings misses and a securities class action lawsuit filed in May 2026 create headwinds, though analyst consensus remains 69% buy-rated.
The outlook is cautious due to litigation overhangs and persistent losses, but low valuations may attract value investors if operational improvements materialize. Key risks include legal liabilities and execution on turning profitability; upside depends on management's ability to stabilize earnings amid competitive pressures in Chinese financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
